Predictors of circumferential resection margin involvement in surgically resected rectal cancer: A retrospective review of 23, 464 patients in the US National Cancer Database. (April 2016)

• Record Type: Journal Article
• Authors: Al-Sukhni, Eisar; Attwood, Kristopher; Gabriel, Emmanuel; Nurkin, Steven J.
• Is Part Of: International journal of surgery. Volume 28(2016)
• Page Start: 112
• Page End: 117
• Publication Date: 2016-04
• Subjects: Rectal neoplasms -- Adenocarcinoma -- Pathology -- Surgical; Surgery -- Periodicals; Surgical Procedures, Operative -- Periodicals; 617.005
• DOI: 10.1016/j.ijsu.2016.01.098
• Languages: English
• ISSNs: 1743-9191

Abstract

Abstract: Introduction: The circumferential resection margin (CRM) is a key prognostic factor after rectal cancer resection. We sought to identify factors associated with CRM involvement (CRM+). Methods: A retrospective review was performed of the National Cancer Database, 2004–2011. Patients with rectal cancer who underwent radical resection and had a recorded CRM were included. Multivariable analysis of the association between clinicopathologic characteristics and CRM was performed. Tumor <1 mm from the cut margin defined CRM+. Results and discussion: Of 23, 464 eligible patients, 13.3% were CRM+. Factors associated with CRM+ were diagnosis later in the study period, lack of insurance, advanced stage, higher grade, undergoing APR, and receiving radiation. Nearly half of CRM+ patients did not receive neoadjuvant therapy. CRM+ patients who did not receive neoadjuvant therapy were more likely to be female, older, with more comorbidities, smaller tumors, earlier clinical stage, advanced pathologic stage, and CEA-negative disease compared to those who received it. Conclusions: Factors associated with CRM+ include features of advanced disease, undergoing APR, and lack of health insurance. Half of CRM+ patients did not receive neoadjuvant treatment. These represent cases where CRM status may be modifiable with appropriate pre-operative selection and multidisciplinary management. Highlights: Nearly half of patients with CRM+ did not receive neoadjuvant therapy and nearly one-third did not receive any radiation. Factors predicting CRM+ included lack of insurance, higher grade, advanced stage, undergoing APR, and receiving radiation. CRM+ patients who did not receive neoadjuvant therapy had earlier disease than those who were CRM+ after neoadjuvant therapy. These findings suggest potential missed opportunities to achieve CRM− and indicate areas to improve rectal cancer care.